|Title:||Asthma Biological Treatment: Review of patient outcomes with severe brittle asthma in Cork University Hospital.|
|Author(s):||Casey D Farrell A O' Sullivan G Murphy J Plant BJ Murphy D|
|Institution:||Cork University Hospital|
|Poster:||Click to view poster|
|Category:||Asthma and COPD|
|Abstract:||A retrospective review was performed of patients with severe asthma on biologic therapy (Omalizumab, Mepolizumab, Resilizumab or Benralizumab) in our centre 45 patients were identified and their outcomes prior to and one year post biologic therapy commencement were analysed. |
73 patients had been initially commenced on monoclonal therapies in our institution. 45 have continued therapy for over 12 months.
We recorded the ACQ score, number of exacerbations, hospital and ITU admissions in the 12 months before and 1 year after commencement of therapy. Antibiotic and steroid use was examined in relation to both exacerbation treatment and prophylaxis.
An 80% reduction in exacerbations and a 75% reduction in hospital admissions, with a subsequent reduction of 403 bed days, which was significant (p= 0.04). There has been a 100% reduction in ICU admissions. ACQ was calculated at a mean score of 3.3 pre biologic therapy. A reduction in ACQ to 1.5 a year post biologics (P=0.005).
There was a 50% reduction in the use of maintenance steroids and an 80% discontinuation rate of prophylactic antibiotics (P=0.004)
Thus biologic therapy significantly improves patient outcomes and should be considered for suitable patients with severe asthma.